ライフサイエンスコーパス: gastrectomy

1 ic procedure (eg, a gastric bypass or sleeve gastrectomy).

2 edures (aortic and mitral valve replacement, gastrectomy).

3 lial CDH1 mutation and subsequently received gastrectomy.

4 previous HER2-targeted therapy, and previous gastrectomy.

5 stric band placement, or laparoscopic sleeve gastrectomy.

6 ains disease-free 36 months after completion gastrectomy.

7 to those of other patients undergoing total gastrectomy.

8 ting a recommendation for prophylactic total gastrectomy.

9 rapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

10 ase after Roux-en-Y gastric bypass or sleeve gastrectomy.

11 alized costs following curative-intent total gastrectomy.

12 , 22 to 30) among those who underwent sleeve gastrectomy.

13 robot-assisted kidney transplant and sleeve gastrectomy.

14 anding, and 60% (95% CI, 51-70) after sleeve gastrectomy.

15 t simultaneous cesarean section and subtotal gastrectomy.

16 bjects aged 25 to 50 years undergoing sleeve gastrectomy.

17 orated gastric ulcers, necessitating a wedge gastrectomy.

18 ble gastric banding, and laparoscopic sleeve gastrectomy.

19 age, 12% transhiatal, and 19% extended total gastrectomy.

20 rapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.

21 er distal (DG), proximal (PG), or total (TG) gastrectomy.

22 pproach for limited, subtotal and even total gastrectomy.

23 ia, age, chronic heart failure, and subtotal gastrectomy.

24 isk of all cardiovascular events than sleeve gastrectomy.

25 randial GLP-1 and PYY increased after sleeve gastrectomy.

26 790 following esophagectomy and 81 following gastrectomy.

27 -Y gastric bypass (RYGB) and vertical sleeve gastrectomy.

28 hey underwent endoscopic examinations and/or gastrectomy.

29 hologic evidence for DGC on endoscopy and/or gastrectomy.

30 geons who over-rated their skill with sleeve gastrectomy (0.65 vs 0.27, p = 0.0181).

31 with curative intent either by laparoscopic gastrectomy (1,477 patients) or open gastrectomy (1,499

32 oscopic gastrectomy (1,477 patients) or open gastrectomy (1,499 patients) between April 1998 and Dece

33 hich included 74% gastric bypass, 15% sleeve gastrectomy, 10% adjustable gastric banding, and 1% othe

34 tudy of 12 patients who had undergone sleeve gastrectomy, 12 patients who had undergone RYGB, and 12

35 nterval [CI], 3.2%-4.0%), followed by sleeve gastrectomy (2.2%; 95% CI, 1.2%-3.2%), and laparoscopic

36 Of 64,537 patients, 46% underwent sleeve gastrectomy, 22% revisited the emergency department (ED)

37 residents (mastectomy 6.5%; colectomy 22.8%; gastrectomy 23.4%; antireflux procedures 23.4%; pancreat

38 bypass (80-90 min operative time) and sleeve gastrectomy (30-45 min operative time), which, to a high

39 g (n=1053), gastric bypass (795), and sleeve gastrectomy (317), with two procedures undefined.

40 After gastrectomy, 397 of 928 patients (42%) had a postoperati

41 sewing of ulcer (7.6% vs. 7.4%), less use of gastrectomy (4.4% vs. 2.1%, P < 0.001), and less use of

42 Hispanics were more likely to require total gastrectomy (51%) compared with whites (38%), African Am

43 e, with the most dramatic increases seen for gastrectomy (54%), pancreatectomy (31%), and thyroidecto

44 Gastric bypass (6.56 kg/mo) and sleeve gastrectomy (6.29 kg/mo) were associated with greater in

45 gastric bypass (161 participants) or sleeve gastrectomy (67) were included in the analysis.

46 n, esophagectomy, colectomy, pancreatectomy, gastrectomy, abdominal aortic aneurysm repair, hip repla

47 43.1; 95% CI, 19.7-94.5), followed by sleeve gastrectomy (adjusted RR, 16.6; 95% CI, 4.7-58.4) and ga

48 For gastrectomies and colectomies, risk-adjusted mortality i

49 MATERIAL/Records of 104 consecutive total gastrectomies and distal esophagectomies were analysed.

50 omesenteric vein thrombosis, 16 after sleeve gastrectomy and 1 following adjustable gastric banding.

51 ed with 19% in patients who underwent sleeve gastrectomy and 16% following gastric banding (P<0.0001)

52 98% laparoscopic (n = 162,969; 69.8% sleeve gastrectomy and 27.8% gastric bypass) in 2016.

53 A total gastrectomy and an esophagectomy for GEJ cancer show lar

54 Both a total gastrectomy and an esophagectomy may be valid treatment

55 d obesity in the United States toward sleeve gastrectomy and away from the adjustable gastric band.

56 iatric surgery (sleeve gastrectomy or sleeve gastrectomy and biliopancreatic diversion with duodenal

57 s, the patient worsened and underwent distal gastrectomy and cholecystectomy that included removing t

58 eoperative chemotherapy followed by adequate gastrectomy and either chemotherapy or chemoradiotherapy

59 odes examined or operative mortality between gastrectomy and esophagectomy.

60 common procedures used currently, the sleeve gastrectomy and gastric bypass, have similar effects on

61 Roux-en-Y gastric bypass or vertical sleeve gastrectomy and had persistent or recurrent type 2 diabe

62 Of the bariatric surgery models, sleeve gastrectomy and mRYGB had higher success rates and lower

63 three had nodal infiltration requiring total gastrectomy and one an adenocarcinoma) and iron-deficien

64 re, we showed that bariatric surgery (sleeve gastrectomy and proximal and distal RYGB) dynamically af

65 of QOL impairment with their patients before gastrectomy and reassure them that most symptoms resolve

66 All primary, laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass procedures betw

67 ients with CKD are not candidates for sleeve gastrectomy and the incremental increased-risk from RYGB

68 surgery (Roux-en-Y gastric bypass and sleeve gastrectomy) and major adverse cardiovascular events in

69 hundred seventy-two esophagectomies, 12,622 gastrectomies, and 9116 pancreatectomies were examined.

70 d from 2 to 29 esophagectomies, from 1 to 14 gastrectomies, and from 2 to 31 pancreatectomies per sur

71 We retrieved data on esophagectomies, gastrectomies, and pancreatectomies for cancer from the

72 paroscopic adjustable gastric band, 0 sleeve gastrectomy, and 0.14% (95% CI, 0.08%-0.25%) of the gast

73 bypass, 56% of patients who underwent sleeve gastrectomy, and 50% of patients following gastric bandi

74 ic Roux-en-Y gastric bypass, vertical sleeve gastrectomy, and adjustable gastric banding were perform

75 ary lobectomy, pneumonectomy, esophagectomy, gastrectomy, and colectomy) for a primary cancer between

76 -19%, and -5% in the gastric-bypass, sleeve-gastrectomy, and medical-therapy groups, respectively),

77 Each additional case of esophagectomy, gastrectomy, and pancreatectomy would reduce 30-day mort

78 Surgical management (gastric banding, sleeve gastrectomy, and Roux-en Y gastric bypass) can produce r

79 setting: common channel 75 to 125 cm, sleeve gastrectomy (approximately 100 mL gastric pouch), closed

80 creating a small-bowel reservoir after total gastrectomy are contended.

81 afety, and durability of laparoscopic sleeve gastrectomy as a definitive therapeutic option for sever

82 timing of payers' decisions to cover sleeve gastrectomy as a natural experiment.

83 essive regimes may be prescribed after total gastrectomy as long as their limitations are noted.

84 sence of a standardized system for recording gastrectomy-associated complications makes it difficult

85 e prospectively enrolled patients undergoing gastrectomy at our institution between 2002 and 2007.

86 to describe postoperative outcomes of total gastrectomy at our institution for patients with heredit

87 ajority of gastric cancer patients underwent gastrectomy at providing hospitals nearest to home, refl

88 Majority (67.1%) of patients underwent gastrectomy at the nearest providing hospitals.

89 Despite sleeve gastrectomy becoming the most common surgical weight los

90 ric bypass or a laparoscopic vertical sleeve gastrectomy between 2007 and 2009 (n = 4088) without rev

91 urable gastric adenocarcinoma that underwent gastrectomy between 2011 and 2015, registered in the Dut

92 CKD patients who underwent RYGB or sleeve gastrectomy between 2015 and 2017 were identified from t

93 I) was 46.01 +/- 4.07 kg/m with a postsleeve gastrectomy BMI of 34.07 +/- 3.73 kg/m, representing tot

94 study was to compare silicone-banded sleeve gastrectomy (BSG) to nonbanded sleeve gastrectomy (SG) r

95 urgical skill varied for laparoscopic sleeve gastrectomy but did not have a significant impact on ove

96 Patients contemplating prophylactic gastrectomy can be reassured about the long-term HRQL ou

97 nvasive treatment regimens involving radical gastrectomy, chemotherapy or radiation, or all.

98 % of 2-, 3-, transhiatal, and extended total gastrectomy cohorts, respectively (P=0.05).

99 phagectomy, pancreatectomy, partial or total gastrectomy, colectomy, lung resection, and cystectomy f

100 Laparoscopic sleeve gastrectomy did not reliably relieve or improve GERD sym

101 ients with CDH1 mutation who underwent total gastrectomy during 2005 to 2015.

102 le gastric banding, and most recently sleeve gastrectomy for both significant weight loss and comorbi

103 mine travel patterns for patients undergoing gastrectomy for cancer and to identify factors associate

104 all patients who had undergone laparoscopic gastrectomy for cancer at 3 teaching institutions betwee

105 dy, all patients undergoing esophagectomy or gastrectomy for cancer between 2016 and 2017 were select

106 ations and evaluate outcomes associated with gastrectomy for cancer in Europe.

107 Laparoscopic gastrectomy for cancer is an advanced procedure with hig

108 all patients who underwent esophagectomy or gastrectomy for cancer with curative intent between 2011

109 ts major short-term outcomes in laparoscopic gastrectomy for cancer.

110 ompted recommendation for total prophylactic gastrectomy for carriers of pathogenic or likely pathoge

111 ll patients undergoing curative-intent total gastrectomy for gastric adenocarcinoma between January 2

112 he optimal regional dissection extent during gastrectomy for gastric adenocarcinoma continues to be d

113 l of 4235 consecutive patients who underwent gastrectomy for gastric adenocarcinoma were identified a

114 ications with hospital costs following total gastrectomy for gastric adenocarcinoma.

115 ost important predictors of recurrence after gastrectomy for gastric adenocarcinoma.

116 date the efficacy and safety of laparoscopic gastrectomy for gastric cancer in terms of long-term sur

117 on perioperative complications revealed that gastrectomy for gastric cancer is still associated with

118 lymphadenectomy during potentially curative gastrectomy for gastric cancer.

119 ers, and overall quality of life after total gastrectomy for gastric malignancy.

120 bed decreased 5-year survival after curative gastrectomy for GC in the West compared with the East.

121 in patients following esophagectomy or total gastrectomy for GEJ cancer.

122 in patients following esophagectomy or total gastrectomy for GEJ cancer.

123 All patients undergoing gastrectomy for nonmetastatic gastric adenocarcinoma reg

124 long-term oncologic outcomes of laparoscopic gastrectomy for patients with gastric cancer were compar

125 ic bypass was found to be superior to sleeve gastrectomy for remission of type 2 diabetes at 1 year a

126 120 patients underwent curative-intent total gastrectomy for stage I through III gastric adenocarcino

127 e oncologic outcomes of laparoscopy-assisted gastrectomy for the treatment of gastric cancer have not

128 Patients who had a sleeve gastrectomy, gastric bypass, or duodenal switch were mor

129 ing the forestomach almost intact (glandular gastrectomy [GG]) and compared subsequent metabolic remo

130 eater in the gastric-bypass group and sleeve-gastrectomy group (-29.4+/-9.0 kg and -25.1+/-8.5 kg, re

131 roup (P<0.001), and 6.6+/-1.0% in the sleeve-gastrectomy group (P=0.003).

132 2) and 37% (18 of 49 patients) in the sleeve-gastrectomy group (P=0.008).

133 oup (P<0.001) and 24% of those in the sleeve-gastrectomy group (P=0.01).

134 the gastric bypass group than in the sleeve gastrectomy group (risk difference 27% [95% CI 10 to 44]

135 stric emptying was accelerated in the sleeve gastrectomy group compared with the other 2 groups (whic

136 c-bypass group and 21.1+/-8.9% in the sleeve-gastrectomy group, as compared with a reduction of 4.2+/

137 In the sleeve gastrectomy group, eight of 55 participants had early co

138 ne observed in the gastric-bypass and sleeve-gastrectomy groups were superior to the changes seen in

139 icant larger than in the nonobese and sleeve gastrectomy groups.

140 roctectomy: >=35/yr, esophagectomy: >=41/yr, gastrectomy: >=16/yr, pancreatectomy: >=26/yr, and hepat

141 (42.5%) who underwent an uncomplicated total gastrectomy had a mean (SD) normalized cost of MP $12330

142 ort of commercially insured patients, sleeve gastrectomy had a superior safety profile to gastric byp

143 ars from surgery, patients undergoing sleeve gastrectomy had fewer re-interventions (sleeve 9.9%, byp

144 alysis demonstrated that patients undergoing gastrectomy had significantly higher odds of having 15 o

145 nses in morbidly obese patients after sleeve gastrectomy has not been determined.

146 Sleeve gastrectomy has rapidly become the most common bariatric

147 Gastric bypass and sleeve gastrectomy have a greater effect than gastric banding.

148 as 35.8% after esophagectomy and 28.4% after gastrectomy (HR 1.2, 95%CI 0.721-1.836, p = 0.557).

149 rgoing colectomy, cystectomy, esophagectomy, gastrectomy, hysterectomy, lung resection, pancreatectom

150 rapy plus Roux-en-Y gastric bypass or sleeve gastrectomy in 150 obese patients with uncontrolled type

151 tric cancer were comparable to those of open gastrectomy in a large-scale, multicenter, retrospective

152 s procedure such as gastric bypass or sleeve gastrectomy in a single procedure.

153 o home, reflecting little regionalization of gastrectomy in California.

154 We performed a novel sleeve gastrectomy in rats that resects approximately 80% of th

155 bidity and mortality after esophagectomy and gastrectomy in the Netherlands according to the definiti

156 CDH1 mutations are an indication for total gastrectomy in these patients.

157 o undergo Roux-en-Y gastric bypass or sleeve gastrectomy in three bariatric centers in the Netherland

158 ence of managing long-term sequelae of total gastrectomy in young patients.

159 Finally, complications after sleeve gastrectomy include postoperative leaks and strictures,

160 taneous fistulas, reconstruction after total gastrectomy, intestinal transit after ileocecal segment

161 robot-assisted kidney transplant and sleeve gastrectomy is feasible in morbidly obese patients and a

162 ts who qualify for bariatric surgery, sleeve gastrectomy is often preferred to RYGB based on percepti

163 Clinical trials comparing laparoscopic gastrectomy (LG) versus traditional open gastrectomy (OG

164 Operative approaches were grouped into gastrectomy (limited esophagectomy) or esophagectomy (ex

165 of revisional surgery to laparoscopic sleeve gastrectomy (LSG) compared to laparoscopic Roux-Y gastri

166 Laparoscopic sleeve gastrectomy (LSG) has been proposed as an effective alte

167 erm metabolic effects of laparoscopic sleeve gastrectomy (LSG) in patients with type 2 diabetes (T2DM

168 techniques to use for a laparoscopic sleeve gastrectomy (LSG) including the use of staple line reinf

169 Laparoscopic sleeve gastrectomy (LSG) increases transplant eligibility by re

170 Laparoscopic sleeve gastrectomy (LSG) is a promising procedure for adolescen

171 The prevalence of laparoscopic sleeve gastrectomy (LSG) is increasing, but data on its long-te

172 Laparoscopic sleeve gastrectomy (LSG) is performed almost as often in Europe

173 tes who underwent either laparoscopic sleeve gastrectomy (LSG) or laparoscopic adjustable gastric ban

174 efore and 3 months after laparoscopic sleeve gastrectomy (LSG).

175 ) patients who underwent laparoscopic sleeve gastrectomy (LSG).

176 ntify operative steps in laparoscopic sleeve gastrectomy (LSG).

177 erwent elective esophagectomy, total/partial gastrectomy, major hepatectomy, and pancreatectomy were

178 and, in particular, gastric bypass or sleeve gastrectomy may be considered as new treatment options f

179 Of the 41 patients undergoing total gastrectomy, median age was 47 years (range 20 to 71).

180 ever, the higher risk of revisions in sleeve gastrectomy merits further exploration.

181 postoperative outcomes of minimally invasive gastrectomy (MIG) to open gastrectomy (OG) for cancer du

182 ents (Roux-en-Y gastric bypass n=465; sleeve gastrectomy n=44) could be matched 1:1 to a control with

183 hagectomy (n = 5), and laparoscopic proximal gastrectomy (n = 1).

184 5 through 2003, 505 patients underwent R0/R1 gastrectomy (n = 153) or esophagectomy (n = 352) without

185 identify all 55,016 inpatients who underwent gastrectomy (n = 6434) or colectomy (n = 48,582) between

186 Roux-en-Y gastric bypass (n = 161), sleeve gastrectomy (n = 67), or laparoscopic adjustable gastric

187 re similar between RYGB (n = 673) and sleeve gastrectomy (n = 673) cohorts.

188 , morbidly obese patients who had had sleeve gastrectomy (n = 8), and nonobese patients (n = 16).

189 her had subtotal resection (n = 29) or total gastrectomy (n = 97) for T1 gastric cancer.

190 assigned to gastric bypass (n=54) or sleeve gastrectomy (n=55).

191 ss, n = 162; gastric banding, n = 32; sleeve gastrectomy, n = 23), a mean excess weight loss (EWL) of

192 minimally invasive gastrectomy (MIG) to open gastrectomy (OG) for cancer during the introduction of M

193 pic gastrectomy (LG) versus traditional open gastrectomy (OG) have been planned, their surgical outco

194 bjective was to assess the effects of sleeve gastrectomy on hunger, satiation, gastric and gallbladde

195 iatric procedures, gastric bypass and sleeve gastrectomy, on remission of diabetes and beta-cell func

196 Patients with GEJ cancer in whom a total gastrectomy or an esophagectomy was performed between 20

197 adiological contrast swallow following total gastrectomy or distal esophagectomy cannot be recommende

198 After gastrectomy or esophagectomy, esophagogastrostomy and es

199 ma levels to be raised in humans after total gastrectomy or intestinal transplantation, but largely u

200 A high-pH environment created by surgical gastrectomy or proton pump inhibitor therapy in combinat

201 nd 8-12 days after bariatric surgery (sleeve gastrectomy or sleeve gastrectomy and biliopancreatic di

202 ial cells (obtained from patients undergoing gastrectomy or sleeve resection or gastric antral organo

203 stric bypass (OR 3.51, CI 2.38-5.22); sleeve gastrectomy (OR 2.46, CI 1.73-3.50).

204 c bypass (OR 3.97, CI 1.77-8.91); and sleeve gastrectomy (OR 3.50, CI 1.30-9.34).

205 , including Roux-en-Y gastric bypass, sleeve gastrectomy, or adjustable gastric banding.

206 ic banding, Roux-en-Y gastric bypass, sleeve gastrectomy, or other/unknown).

207 ined resection of the adjacent organs with a gastrectomy owing to suspicion or direct invasion of the

208 rwent colectomy, proctectomy, esophagectomy, gastrectomy, pancreatectomy, and hepatectomy for cancer

209 ed for colorectal procedures, esophagectomy, gastrectomy, pancreatectomy, thyroidectomy, coronary art

210 der patients (>/=65 years of age) undergoing gastrectomy, pancreaticoduodenectomy, and colectomy at a

211 ere 1:1 propensity-score matched with sleeve gastrectomy patients based on preoperative factors that

212 Among the surgical cohort, sleeve gastrectomy patients had a higher risk of developing MI,

213 Sleeve gastrectomy patients showed the lowest ghrelin concentra

214 y obese and nonobese groups; however, sleeve gastrectomy patients were less hungry and more satiated

215 mong well-matched cohorts of RYGB and sleeve gastrectomy patients, incidence of primary outcomes were

216 A total of 1349 gastrectomies performed between January 2017 and Decembe

217 There were 14 955 esophagectomies and 10 671 gastrectomies performed in 141 units.

218 for gastric bypass, gastric band, or sleeve gastrectomy performed on patients with a body mass index

219 e traveled and rate of bypassing the nearest gastrectomy-performing hospitals.

220 s if they had a laparoscopic vertical sleeve gastrectomy procedure and a higher BMI at surgery, were

221 Roux-en-Y gastric bypass and vertical sleeve gastrectomy, produce significant and durable weight loss

222 istinct bariatric procedures [i.e., a sleeve gastrectomy, proximal Roux-en Y gastric bypass (RYGB), a

223 is generally to undertake prophylactic total gastrectomy (PTG).

224 Gastrectomy remains a major operation with potential for

225 ide and prognosis after potentially curative gastrectomy remains poor.

226 Prophylactic total gastrectomy remains the recommended option for gastric c

227 y between 2012 and 2016, the share of sleeve gastrectomy rose from 52.6% (2012) to 75% (2016).

228 ry models, including gastric banding, sleeve gastrectomy, Roux-en-Y gastric bypass (RYGB), modified R

229 surgery, including bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass), colorectal surge

230 Sleeve gastrectomy seems to be associated with profound changes

231 Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) account for >95% of bariatric procedure

232 Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) ind

233 objective was to study the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGBP) on

234 ted a video of a typical laparoscopic sleeve gastrectomy (SG) between 2015-2016.

235 Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG) have been associated with a high remiss

236 f Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in Sweden, Norway, and the Netherlands.

237 Laparoscopic sleeve gastrectomy (SG) is an upcoming procedure in bariatric s

238 Although sleeve gastrectomy (SG) is growing in favor, some randomized tr

239 nically challenging procedure such as sleeve gastrectomy (SG) is unknown.

240 sleeve gastrectomy (BSG) to nonbanded sleeve gastrectomy (SG) regarding weight loss, obesity-related

241 s, and Barrett's esophagus (BE) after sleeve gastrectomy (SG) through a systematic review and meta-an

242 study was to compare the influence of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB)

243 glucose tolerance commonly seen after sleeve gastrectomy (SG), several observations challenge this hy

244 sociated with reflux events following sleeve gastrectomy (SG).

245 adjustable gastric banding (AGB), or sleeve gastrectomy (SG).

246 th obese rodents and humans following sleeve-gastrectomy (SG).

247 and (AGB) to gastric bypass (RYGB) or sleeve gastrectomy (SG).

248 ate of insulin cessation (71.7%) than sleeve gastrectomy (SG; 64.5%; RR 0.92, confidence interval (CI

249 Total gastrectomy should be considered for all CDH1 mutation c

250 The banded versus nonbanded sleeve gastrectomy single-center, randomized controlled trial w

251 hylcytosine (anti-5-methyl-C) in a series of gastrectomy specimens showed frequent loss of methylatio

252 heir primary tumor biopsies from 11 esophago-gastrectomy specimens were examined and analyzed by DESI

253 ral necrosis in 9/11 esophagectomy and 16/16 gastrectomy specimens.

254 cohorts, 5 retrospective cohorts) and sleeve gastrectomy studies (2 retrospective cohorts) had 95% co

255 evisions were slightly more common in sleeve gastrectomy than in gastric bypass (sleeve 0.6%, bypass

256 ed (1:1) to receive gastric bypass or sleeve gastrectomy (the Oseberg study).

257 After vertical sleeve gastrectomy, the level of BA increased [total: 1.17 +/-

258 ding to SES ranged from 1.04 (0.95-1.14) for gastrectomy to 1.45 (1.21-1.73) for pancreatectomy.

259 Prior studies comparing sleeve gastrectomy to gastric bypass are limited by low sample

260 le of imaging studies to localize tumor, and gastrectomy to manage acid output.

261 ch, bariatric-specific data comparing sleeve gastrectomy to the adjustable gastric band, and the gast

262 11 of 47 patients (23%) who underwent sleeve gastrectomy (unadjusted P=0.03, adjusted P=0.07, P=0.17

263 confounding, we use the prior year's sleeve gastrectomy utilization within each state as an instrume

264 Annual gastrectomy volumes for nearest and for destination hosp

265 rance claims data to compare vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) wi

266 diabetes outcomes following vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB).

267 diate part of the effects of vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass surgeries

268 -Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) and to identify potential taste-relate

269 In a mouse model, vertical sleeve gastrectomy (VSG) caused trabecular and cortical bone lo

270 Vertical sleeve gastrectomy (VSG) has recently surpassed gastric bypass

271 Vertical sleeve gastrectomy (VSG) involves the resection of ~ 80% of the

272 Vertical sleeve gastrectomy (VSG) is an effective therapeutic approach f

273 er the beneficial effects of vertical sleeve gastrectomy (VSG) on plasma lipid levels are weight inde

274 s of restricted weight gain: vertical sleeve gastrectomy (VSG) or food restriction.

275 Vertical sleeve gastrectomy (VSG) produces dramatic, sustained weight lo

276 Vertical sleeve gastrectomy (VSG) produces sustainable weight loss, remi

277 -Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) reduce weight and improve glucose meta

278 -Y-Gastric Bypass (RYGB) and Vertical Sleeve Gastrectomy (VSG) surgery and that these changes would i

279 his hypothesis, we performed vertical sleeve gastrectomy (VSG), a surgery with clinical efficacy very

280 iatric procedures, including vertical sleeve gastrectomy (VSG), and has been widely hypothesized to c

281 surgical procedures, such as vertical sleeve gastrectomy (VSG), are at present the most effective the

282 n-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG), are the most effective approaches to

283 -en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), oral glucose administration, and type

284 nd diet preference following vertical sleeve gastrectomy (VSG).

285 variable outcomes following vertical sleeve gastrectomy (VSG).

286 diabetes mellitus undergoing vertical sleeve gastrectomy was also recruited (n = 12) as a comparison.

287 n of East Asian origin with a previous total gastrectomy was evaluated for living donor kidney transp

288 atients have durable weight loss after total gastrectomy, weights stabilize at about 6 to 12 months p

289 All partial gastrectomies were performed using a 50F bougie.

290 Histological slides from 124 primary gastrectomies were reviewed and their pathological repor

291 18,043 gastric cancer patients who underwent gastrectomy were identified from the US Surveillance, Ep

292 Total (46.1%) and subtotal (46.4%) gastrectomy were the predominant resections.

293 reast carcinoma underwent prophylactic total gastrectomy which revealed multifocal intramucosal signe

294 mplication rates of patients who underwent a gastrectomy with a combined resection of the involved or

295 atients in the CRITICS trial who underwent a gastrectomy with curative intent in a Dutch hospital wer

296 Subsequently, they each underwent total gastrectomy with D-2 node dissection and Roux-en-Y esoph

297 e decision between endoscopic mucosectomy or gastrectomy with lymphadenectomy for early gastric cance

298 He underwent a subtotal gastrectomy with Roux-en-Y gastrojejunostomy along with

299 eft mastectomy for breast cancer and partial gastrectomy with Roux-en-Y reconstruction for nonhealing

300 ctional and nutritional outcomes after total gastrectomy, without greater perioperative morbidity.